Why GLP-1s Don't Start at Full Dose
Every GLP-1 medication — whether injectable or oral — follows a titration schedule that starts at a low dose and gradually increases over weeks to months. This isn't optional caution; it's built into the FDA-approved prescribing information for a specific reason. GLP-1 receptor agonists slow gastric emptying, reduce appetite, and affect gut motility. Introducing these effects gradually gives your gastrointestinal system time to adapt, which significantly reduces the severity of the most common side effects: nausea, vomiting, diarrhea, and constipation.
Skipping titration steps or escalating too quickly increases the risk of severe GI side effects, which is the leading cause of patients discontinuing GLP-1 therapy. The titration process is designed to keep you on the medication long enough to see meaningful results.
Titration Schedules by Medication
| Medication | Starting Dose | Maintenance Dose | Time to Maintenance |
|---|---|---|---|
| Wegovy (sema injection) | 0.25 mg/week | 2.4 mg/week | ~16–20 weeks |
| Wegovy HD | 0.25 mg/week | 7.2 mg/week | ~28+ weeks |
| Wegovy pill | 1.5 mg/day | 25 mg/day | ~12–16 weeks |
| Zepbound (tirz injection) | 2.5 mg/week | 10–15 mg/week | ~20–28 weeks |
| Foundayo (orforglipron) | 0.8 mg/day | 9–17.2 mg/day | ~20+ weeks |
| Ozempic (sema injection) | 0.25 mg/week | 1–2 mg/week | ~8–12 weeks |
What Each Phase Feels Like
Weeks 1-4: The Adjustment Period
At the starting dose, you may notice mild appetite suppression, but weight loss at this stage is typically minimal. The primary purpose of the first month is to let your body adjust to the medication's effects on gastric emptying and gut motility. Mild nausea is common but usually manageable. Eat smaller meals, stay hydrated, and avoid greasy or heavy foods.
Weeks 4-12: Building Toward Therapeutic Levels
As your dose increases through the intermediate steps, appetite suppression becomes more noticeable. Many patients report a significant change in their relationship with food — reduced cravings, earlier satiety, and less preoccupation with meals. Weight loss typically becomes measurable during this phase. GI side effects may flare briefly with each dose increase before settling down.
Weeks 12+: Maintenance Phase
Once you reach your target maintenance dose, the appetite-suppressing effects should be well-established. Weight loss continues at a steady pace — most clinical trials show the greatest total weight loss occurring over 12 to 18 months of continued therapy. GI side effects have usually resolved or become very mild by this point.
When Your Provider Might Adjust the Plan
Titration isn't always a straight line from starting dose to maximum dose. Your provider may modify the schedule based on several factors. If side effects are severe at a particular dose, they may hold you at that dose for an additional month before escalating, or they may reduce the dose temporarily. If you're achieving good results at a lower dose, there may be no clinical reason to push to the maximum — many patients maintain effective weight loss at intermediate doses. If you hit a plateau, your provider may increase to the next dose level to see if additional response is achievable.
What Happens If You Miss Doses During Titration
Consistency is important during titration because your body is adapting to progressively higher drug levels. If you miss a single dose of a daily medication (Foundayo, Wegovy pill), take it as soon as you remember and continue your regular schedule. For weekly injections (Wegovy, Zepbound), if you miss a dose by more than a few days, your provider may recommend repeating the current dose level rather than escalating.
Extended interruptions (a week or more for daily medications, two or more missed doses for weekly injections) may require restarting titration from a lower dose. Don't try to "catch up" by taking extra doses — this increases the risk of severe GI side effects.
Why Patience During Titration Pays Off
The titration phase can feel frustratingly slow when you're eager to see results. But the data strongly supports the gradual approach: patients who complete the full titration schedule have significantly higher rates of long-term medication adherence and, as a result, greater total weight loss over 12 to 18 months. The titration period is an investment in your ability to stay on the medication long enough for it to work.
In the ATTAIN-1 trial, patients on Foundayo who completed the full titration to the highest dose achieved approximately 11% body weight loss over 72 weeks. In the STEP trials, patients on Wegovy who completed titration to 2.4mg per week achieved roughly 15% weight loss over 68 weeks. These results required months of consistent therapy — not days or weeks.